CVE:FLWRFlowr Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Flowr Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.59 +0.01 (+1.72 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.57Now: C$0.59▼C$0.6150-Day RangeC$0.53MA: C$0.59▼C$0.6952-Week RangeC$0.32Now: C$0.59▼C$7.50Volume133,059 shsAverage Volume151,697 shsMarket CapitalizationC$64.56 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media The Flowr Corporation cultivates and produces medicinal cannabis in Canada. The company is based in Lake Country, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingFlowr has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$3.05, Flowr has a potential upside of 416.9% from its current price of C$0.59.Amount of Analyst CoverageFlowr has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesFlowr has received 36 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFlowr has received 39 “underperform” votes. (Add your “underperform” vote.)Community SentimentFlowr has received 52.00% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Flowr and other stocks. Vote “Outperform” if you believe FLWR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FLWR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFlowr does not currently pay a dividend.Dividend GrowthFlowr does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Flowr insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Flowr are expected to decrease by -100.00% in the coming year, from C$0.02 to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Flowr is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Flowr is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFlowr has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:FLWR Previous Symbol CUSIPN/A CIKN/A Webwww.flowr.ca Phone905-940-3993Debt Debt-to-Equity Ratio15.50 Current Ratio1.85 Quick Ratio1.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio29.50 P/E GrowthN/A Sales & Book Value Annual SalesC$7.62 million Price / Sales8.47 Cash FlowC$0.23 per share Price / Cash Flow2.55 Book ValueC$1.40 per share Price / Book0.42Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees78 Outstanding Shares109,427,000Market CapC$64.56 million Next Earnings DateN/A OptionableNot Optionable TSXV:FLWR Rates by TradingView Receive FLWR News and Ratings via Email Sign-up to receive the latest news and ratings for FLWR and its competitors with MarketBeat's FREE daily newsletter. Flowr (CVE:FLWR) Frequently Asked Questions How has Flowr's stock been impacted by COVID-19 (Coronavirus)? Flowr's stock was trading at C$0.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FLWR shares have increased by 18.0% and is now trading at C$0.59. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Flowr? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flowr in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Flowr. What price target have analysts set for FLWR? 2 equities research analysts have issued 1 year price objectives for Flowr's stock. Their forecasts range from C$2.10 to C$4.00. On average, they expect Flowr's share price to reach C$3.05 in the next twelve months. This suggests a possible upside of 416.9% from the stock's current price. View analysts' price targets for Flowr. Has Flowr been receiving favorable news coverage? News headlines about FLWR stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Flowr earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View the latest news aboutFlowr. Who are some of Flowr's key competitors? Some companies that are related to Flowr include ICC Labs (ICC), Amryt Pharma (AMYT), Benchmark (BMK), ESSA Pharma (EPI), Probiotec (PBP), Green Organic Dutchman (TGOD), WeedMD (WMD), CannTrust (TRST), Supreme Cannabis (FIRE), Shield Therapeutics (STX), Althea Group (AGH), Delta 9 Cannabis (NINE), Biosyent (RX), InMed Pharmaceuticals (IN) and Acerus Pharmaceuticals (ASP). View all competitors. What other stocks do shareholders of Flowr own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flowr investors own include Aurora Cannabis (ACB), Cross Timbers Royalty Trust (CRT), Curaleaf (CURLF), Allena Pharmaceuticals (ALNA), Ring Energy (REI), Ring Energy (REI), Two Harbors Investment (TWO), Aurora Cannabis (ACBFF), Advanced Emissions Solutions (ADES) and AGNC Investment (AGNC). Who are Flowr's key executives? Flowr's management team includes the following people: Mr. Vinay Tolia, Co-CEO & Exec. Director (Age 39)Mr. Thomas Flow, Co-Founder, Co-CEO & Exec. Director (Age 41)Mr. Alexander Dann BBA, CPA, CA, Chief Financial Officer (Age 53)Dr. Lyle Oberg, Chief Policy & Medical Officer and Exec. Director (Age 59)Mr. Lance Emanuel, Pres What is Flowr's stock symbol? Flowr trades on the Canadian Venture Exchange (CVE) under the ticker symbol "FLWR." How do I buy shares of Flowr? Shares of FLWR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Flowr's stock price today? One share of FLWR stock can currently be purchased for approximately C$0.59. How big of a company is Flowr? Flowr has a market capitalization of C$64.56 million and generates C$7.62 million in revenue each year. Flowr employs 78 workers across the globe. What is Flowr's official website? The official website for Flowr is www.flowr.ca. How can I contact Flowr? The company can be reached via phone at 905-940-3993. This page was last updated on 6/6/2020 by MarketBeat.com Staff
